News
Watch
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|July 11, 2024

Limitations on Optimal Biomarker Testing Rates

A panel of experts discuss the current limitations of optimal biomarker testing rates in the community.

Episodes in this series

EP. 1 Biomarker Testing and Guideline-Recommended Care in mNSCLC

EP. 1 Biomarker Testing and Guideline-Recommended Care in mNSCLC

EP. 2 Strategies to Increase Biomarker Testing Rates

EP. 2 Strategies to Increase Biomarker Testing Rates

EP. 3 Limitations on Optimal Biomarker Testing Rates

EP. 3 Limitations on Optimal Biomarker Testing Rates

EP. 4 Impact of Biomarker Testing on Treatment Selection and Outcomes

EP. 4 Impact of Biomarker Testing on Treatment Selection and Outcomes

EP. 5 Key Challenges and Unmet Needs in Newly Diagnosed Driver-Negative mNSCLC

EP. 5 Key Challenges and Unmet Needs in Newly Diagnosed Driver-Negative mNSCLC

EP. 6 NCCN Recommendations by PD-L1 Expression Level

EP. 6 NCCN Recommendations by PD-L1 Expression Level

EP. 7 Limitations of NCCN PD-L1 Expression Recommendations

EP. 7 Limitations of NCCN PD-L1 Expression Recommendations

EP. 8 Emerging Data and Evidence for Dual Immunotherapy plus Chemotherapy in First-Line mNSCLC

EP. 8 Emerging Data and Evidence for Dual Immunotherapy plus Chemotherapy in First-Line mNSCLC

EP. 9 Genetic Alterations Impacting Treatment Response and Biomarker Testing Rates in mNSCLC

EP. 9 Genetic Alterations Impacting Treatment Response and Biomarker Testing Rates in mNSCLC

EP. 10 Molecular Characteristics Beyond Mutations Influencing Immunotherapy Response

EP. 10 Molecular Characteristics Beyond Mutations Influencing Immunotherapy Response

A panel of 4 experts on lung cancer

EP. 11 Clinical Factors Impacting Immunotherapy Response and Optimizing Patient Selection

A panel of 4 experts on lung cancer

EP. 12 Overcoming Immunotherapy Resistance: Identifying Non-Responders and Novel Approaches

A panel of 4 experts on lung cancer

EP. 13 Key Takeaways on Enhancing Outcomes for mNSCLC Without Targetable Driver Mutations

Video content above is prompted by the following:

What may currently limit optimal biomarker testing rates in the community?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Newer Agents, New Advantages: Brexpiprazole, Cariprazine, and Lumateperone in MDD

ByKen Cohen, MD,Samuel Wilkinson, MD,Greg Rhee, PhD, FACE,Michael E. Thase, MD,Nisha Bhide, PharmD

September 11th 2026

Dosing, Tolerability, and Formulary Impact: Aripiprazole and Quetiapine XR in MDD

ByKen Cohen, MD,Samuel Wilkinson, MD,Greg Rhee, PhD, FACE,Michael E. Thase, MD,Nisha Bhide, PharmD

September 11th 2026

2 experts are featured in this video

Inside the Be-Well Trials: Design, Population, and Patient Selection

ByRaymond Chung, MD,Douglas Dieterich, MD

September 10th 2026

Counseling Vitiligo Patients on Time to Repigmentation

ByRyan Haumschild, PharmD, MBA,David Rosmarin, MD,Seemal R. Desai, MD, FAAD,Jason Fehr, MA,Karan Lal, DO, MS, FAAD

September 10th 2026

Cross-Trial Vitiligo Data: What Payers Can and Can't Compare

ByRyan Haumschild, PharmD, MBA,David Rosmarin, MD,Seemal R. Desai, MD, FAAD,Jason Fehr, MA,Karan Lal, DO, MS, FAAD

September 10th 2026

Trending on AJMC

Newer Agents, New Advantages: Brexpiprazole, Cariprazine, and Lumateperone in MDD

Dosing, Tolerability, and Formulary Impact: Aripiprazole and Quetiapine XR in MDD

60% of US Women Face Barriers to Postpartum, Mental Health Care

Counseling Vitiligo Patients on Time to Repigmentation

Cross-Trial Vitiligo Data: What Payers Can and Can't Compare